6-K
Biodexa Pharmaceuticals Plc (BDRX)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2023
Commission File Number: 001-37652
Biodexa Pharmaceuticals PLC (Translation of registrant's name into English)
1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]
This Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-233901) and Form F-1 (File No. 333-240984).
SUBMITTED HEREWITH
Attached to the Registrant’s Form 6-K filing for the month of May 2023, and incorporated by reference herein, is:
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release, dated May 22, 2023 entitled "Posting of Annual Report & Notice of AGM" |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Biodexa Pharmaceuticals PLC | |
|---|---|
| (Registrant) | |
| Date: May 22, 2023 | /s/ Stephen Stamp |
| Stephen Stamp | |
| Chief Executive Officer, Chief Financial Officer |
Exhibit Index
| Exhibit Number | Description |
|---|---|
| 99.1 | Press Release, dated May 22, 2023 entitled "Posting of Annual Report & Notice of AGM" |
EdgarFiling
EXHIBIT 99.1
Posting of Annual Report & Notice of AGM
Biodexa Pharma ceuticals PLC (“Biodexa” or the “Company”)
Posting of Annual Report & Notice of AGM
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain announces that its Notice of Annual General Meeting (“AGM”) was posted to shareholders today, along with the Annual Report for the year ended 31 December 2022. The document is also available on the “Investors” section of the Company’s website at www.biodexapharma.com/investors/financial-reports-accounts.
The 2023 AGM will be held at the Company’s offices at 12.00 noon at 1 Caspian Point, Caspian Way, Cardiff CF10 4DQ on 14 June 2023.
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 20480180
www.biodexapharma.com
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma.
MTX110 is a liquid formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com